Oral KT-621 Pill Matches Dupilumab Efficacy, Threatens $20B Market
Kymera Therapeutics’ oral STAT6 degrader KT-621 produced results in Phase 1b at four weeks that matched or exceeded Regeneron’s injectable dupilumab across every clinical endpoint in atopic dermatitis patients. Regeneron’s dupilumab addresses a roughly $20 billion Type 2 immuno-inflammatory market serving only 2 million of 50 million moderate-to-severe patients.
1. KT-621 Phase 1b Efficacy vs Dupilumab
Kymera’s oral STAT6 degrader KT-621 delivered at four weeks efficacy results in atopic dermatitis patients that matched or numerically exceeded those seen with Regeneron’s injectable dupilumab across every clinical endpoint evaluated in a Phase 1b study.
2. Market and Patient Opportunity
Regeneron’s dupilumab serves a Type 2 immuno-inflammatory market estimated at $20 billion annually, addressing roughly 2 million of the 50 million moderate-to-severe patients globally, leaving a large pool of untreated individuals who could shift to an effective oral therapy.
3. Implications for Regeneron
An oral once-daily pill demonstrating parity with dupilumab could pressure Regeneron’s market share and pricing power, prompting potential strategic responses such as formulation improvements, patent extensions, or combination therapies to defend its leading biologic franchise.